Merck sees 2022 sales up nearly 20%, mostly on molnupiravir
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Cantor Fitzgerald Reiterates Merck (MRK) at Overweight on Earnings, Pipeline and Growth "Remains Underappreciated"
February 3, 2022 7:44 AM ESTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $107.00 price target on Merck (NYSE: MRK), following the company's Q4 earnings report.
The analyst quotes: "Post a 4Q21 sales and EPS beat, and ahead of a strong outlook for 2022, we are... More
